In addition, serum CXCL13 and galectin-9 were considered excellent for discriminating high-risk and low-risk CLL patients with cut-off values ≥ 195 pg/mL and ≥ 860 pg/mL, respectively (p values < 0.0001). Here, LGALS9 is linked to B-cell chronic lymphocytic leukemia.